https://www.yiliao.com/index.php?action=history&feed=atom&title=%E6%B3%B0%E7%AB%8B%E5%94%AF
泰立唯 - 版本历史
2026-04-18T11:02:29Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=%E6%B3%B0%E7%AB%8B%E5%94%AF&diff=314009&oldid=prev
2026年1月12日 (一) 03:04 223.160.138.80
2026-01-12T03:04:35Z
<p></p>
<a href="https://www.yiliao.com/index.php?title=%E6%B3%B0%E7%AB%8B%E5%94%AF&diff=314009&oldid=314008">显示更改</a>
223.160.138.80
https://www.yiliao.com/index.php?title=%E6%B3%B0%E7%AB%8B%E5%94%AF&diff=314008&oldid=prev
2026年1月12日 (一) 03:01 223.160.138.80
2026-01-12T03:01:20Z
<p></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="zh-Hans-CN">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">←上一版本</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">2026年1月12日 (一) 03:01的版本</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l3" >第3行：</td>
<td colspan="2" class="diff-lineno">第3行：</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> <del class="diffchange diffchange-inline"><strong></del>[[泰立唯]]<del class="diffchange diffchange-inline"></strong></del>（<del class="diffchange diffchange-inline"><strong></del>[[Talvey]]<del class="diffchange diffchange-inline"></strong></del>），通用名为<del class="diffchange diffchange-inline"><strong></del>[[塔奎单抗]]**（**[[Talquetamab]]**），研发代码为 **[[JNJ-64407564]]**，是由[[强生]]（[[Johnson & Johnson]]）研发的一种全球首创、人源化 <strong>[[GPRC5D/CD3双特异性抗体]]<del class="diffchange diffchange-inline"></strong></del>。该药通过同时结合 T 细胞表面的 <strong>[[CD3]]<del class="diffchange diffchange-inline"></strong> </del>受体和恶性浆细胞表面的 <strong>[[GPRC5D]]<del class="diffchange diffchange-inline"></strong></del>（G蛋白偶联受体C组5家族成员D），诱导 T 细胞重定向并激活免疫杀伤。作为首个针对非 BCMA 靶点的骨髓瘤双抗，泰立唯为 **[[复发或难治性多发性骨髓瘤]]**（[[RRMM]]）患者，尤其是 <strong>[[BCMA]]<del class="diffchange diffchange-inline"></strong> </del>疗法失效后的患者，提供了全新的治疗途径。</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> [[泰立唯]]（[[Talvey]]），通用名为[[塔奎单抗]]**（**[[Talquetamab]]**），研发代码为 **[[JNJ-64407564]]**，是由[[强生]]（[[Johnson & Johnson]]）研发的一种全球首创、人源化 <strong>[[GPRC5D/CD3双特异性抗体]]。该药通过同时结合 T 细胞表面的 <strong>[[CD3]] 受体和恶性浆细胞表面的 <strong>[[GPRC5D]]（G蛋白偶联受体C组5家族成员D），诱导 T 细胞重定向并激活免疫杀伤。作为首个针对非 BCMA 靶点的骨髓瘤双抗，泰立唯为 **[[复发或难治性多发性骨髓瘤]]**（[[RRMM]]）患者，尤其是 <strong>[[BCMA]] 疗法失效后的患者，提供了全新的治疗途径。</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </p></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </p></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></div></td></tr>
<tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l115" >第115行：</td>
<td colspan="2" class="diff-lineno">第115行：</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline"> </del></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> </div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline"> </ins></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> [1] <strong>Chari A, et al. (2022).</strong> <em>Talquetamab, a T-Cell–Redirection Receptor Tyrosine Kinase–like Orphan Receptor 1 Antibody, in Myeloma.</em> <strong>[[The New England Journal of Medicine]]</strong>.<br></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> [1] <strong>Chari A, et al. (2022).</strong> <em>Talquetamab, a T-Cell–Redirection Receptor Tyrosine Kinase–like Orphan Receptor 1 Antibody, in Myeloma.</em> <strong>[[The New England Journal of Medicine]]</strong>.<br></div></td></tr>
</table>
223.160.138.80
https://www.yiliao.com/index.php?title=%E6%B3%B0%E7%AB%8B%E5%94%AF&diff=314007&oldid=prev
223.160.138.80：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-12T03:00:57Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[泰立唯]]</strong>（<strong>[[Talvey]]</strong>），通用名为<strong>[[塔奎单抗]]**（**[[Talquetamab]]**），研发代码为 **[[JNJ-64407564]]**，是由[[强生]]（[[Johnson & Johnson]]）研发的一种全球首创、人源化 <strong>[[GPRC5D/CD3双特异性抗体]]</strong>。该药通过同时结合 T 细胞表面的 <strong>[[CD3]]</strong> 受体和恶性浆细胞表面的 <strong>[[GPRC5D]]</strong>（G蛋白偶联受体C组5家族成员D），诱导 T 细胞重定向并激活免疫杀伤。作为首个针对非 BCMA 靶点的骨髓瘤双抗，泰立唯为 **[[复发或难治性多发性骨髓瘤]]**（[[RRMM]]）患者，尤其是 <strong>[[BCMA]]</strong> 疗法失效后的患者，提供了全新的治疗途径。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">泰立唯 (Talvey)</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">塔奎单抗 · Talquetamab · JNJ-7564</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">Talvey: First-in-class GPRC5D targeted bispecific antibody</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶点：[[GPRC5D]] & [[CD3]]</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">[[Entrez]]ID</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">8343 ([[GPRC5D]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]]ID</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">14068</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">Q8NFJ5</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">约 147,000 Da</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">给药途径</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">皮下注射 (SC)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">研发厂家</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[强生]] (J&J)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">审批状态</th><br />
<td style="padding: 12px; color: #16a34a;">NMPA/FDA 已批准</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：多靶点免疫重定向</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[泰立唯]]的作用机制建立在 <strong>[[T细胞重定向]]</strong> 技术之上，通过双特异性桥接绕过 MHC 限制性直接激活免疫系统：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>GPRC5D 靶向：</strong> <strong>[[GPRC5D]]</strong> 是一种在恶性浆细胞上高度表达的孤儿受体，其表达水平独立于 BCMA。泰立唯利用这一特点，可以清除对 BCMA 疗法产生耐药（如抗原下调或丢失）的肿瘤克隆。</li><br />
<li style="margin-bottom: 12px;"><strong>CD3 介导激活：</strong> 药物的另一臂结合 T 细胞表面的 CD3 ε链，诱导效应 T 细胞向肿瘤细胞聚集并释放 <strong>[[穿孔素]]</strong> 和颗粒酶，导致浆细胞裂解。</li><br />
<li style="margin-bottom: 12px;"><strong>角化组织表达相关：</strong> 由于 GPRC5D 在皮肤、指甲及舌乳头等硬角化组织中也有表达，泰立唯具有独特的非血液学副作用图谱。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">核心临床研究矩阵 (MonumenTAL-1)</h2><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">治疗线次/组别</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">关键疗效指标 (ORR)</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">深度缓解 (>=VGPR)</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">0.4 mg/kg (每周给药)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>74.1%</strong></td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">约 59%</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">BCMA 经治组</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>72.0%</strong></td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">展现出极佳的后线挽救价值</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">安全性特征</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">CRS 发生率高 (70%+)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">多为 1-2 级，安全性可控</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊疗策略：阶梯给药与非血液学管理</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[泰立唯]]在 2026 年的临床应用中强调“<strong>[[分步激活与副作用精细化支持]]</strong>”：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>阶梯剂量爬坡 (Step-up Dosing)：</strong> 为降低首剂效应带来的严重 <strong>[[CRS]]</strong> 风险，必须严格执行阶梯给药。前两次小剂量给药期间，患者通常需住院监测体温与循环状态。</li><br />
<li style="margin-bottom: 12px;"><strong>口腔及皮肤支持：</strong> 针对 <strong>[[味觉障碍]]</strong>（Dysgeusia）和口干，建议采取局部加湿、唾液替代品或营养咨询。皮肤干燥及指甲营养不良需定期使用局部润肤剂和物理保护措施。</li><br />
<li style="margin-bottom: 12px;"><strong>感染预防：</strong> 由于 T 细胞的高度活化及 B 细胞功能的潜在抑制，需定期监测免疫球蛋白水平，并在必要时补充 <strong>[[IVIG]]</strong>。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[GPRC5D]]：</strong> 骨髓瘤治疗的新兴“次世代靶点”，其浆细胞特异性可与 BCMA 媲美。</li><br />
<li style="margin-bottom: 8px;"><strong>[[味觉障碍]]：</strong> 泰立唯最显著的特异性副反应，约 70% 的患者会出现味觉改变。</li><br />
<li style="margin-bottom: 8px;"><strong>[[DuoBody平台]]：</strong> 强生采用的专利技术，用于构建性质稳定的双特异性 IgG4。</li><br />
<li style="margin-bottom: 8px;"><strong>[[现货型药物]]：</strong> 相比 CAR-T 疗法，泰立唯无需制备期，可实现“即买即用”。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Chari A, et al. (2022).</strong> <em>Talquetamab, a T-Cell–Redirection Receptor Tyrosine Kinase–like Orphan Receptor 1 Antibody, in Myeloma.</em> <strong>[[The New England Journal of Medicine]]</strong>.<br><br />
<span style="color: #475569;">[权威点评]：MonumenTAL-1 试验数据确立了泰立唯在多线耐药骨髓瘤中的突破性地位，特别是为 BCMA 经治患者提供了生存希望。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Verhaegen M, et al. (2024/2026 update).</strong> <em>Management of unique toxicities associated with GPRC5D-targeted bispecific antibodies.</em> <strong>[[The Lancet Haematology]]</strong>.[Academic Review]<br><br />
<span style="color: #475569;">[学术点评]：该综述详细解析了泰立唯的角化组织毒性管理，对临床维持治疗期间的患者生活质量保障具有重要指导意义。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
泰立唯 (Talvey) 诊疗生态 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[GPRC5D]]•[[CD3E]]•[[BCMA]]•[[CD38]]•[[FcRH5]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">同类竞品</td><br />
<td style="padding: 10px 15px; color: #334155;">[[泰立奇]] (BCMA双抗)•[[西达基奥仑赛]] (CAR-T)•[[RG6234]] (罗氏 GPRC5D 双抗)</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关键实体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[强生]] (J&J)•[[杨森制药]]•[[FDA]]•[[NMPA]]•[[NCCN指南]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">前沿方向</td><br />
<td style="padding: 10px 15px; color: #334155;">[[RedirecTT-1三联方案]]•[[针对髓外病变的序贯治疗]]•[[固定疗程停药探索]]•[[双靶点双特异性抗体研发]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.80